Revealing mechanisms, biomarkers, and early toxicity to help Amply prioritise their pipeline with real biological evidence.

Sentinal4D worked with Amply using our SCOUT model to analyse their developing asset library. SCOUT rapidly revealed each compound’s mechanism of action, uncovered off-target liabilities, and identified biomarkers that predict which cell types and genetic backgrounds the drug is most likely to work in. By integrating SCOUT’s morphological readouts with our deep proteomic datasets, we also detected early toxicity signatures that standard assays miss ; giving Amply a clear, evidence-driven basis for pipeline prioritisation.